Clinical research
Esperion announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association Scientific Sessions in Philadelphia on Sunday, November 17, 2019.
It was the first randomized, controlled trial comparing Toujeo to Gla-100 in this patient population.
uniQure N.V. announced the publication of 26-week interim data from the ongoing Phase IIb clinical trial of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B, in the journal, Blood Advances.
On the same day Novartis announced that its Cosentyx didn’t prove itself superior to AbbVie’s Humira in psoriatic arthritis, AbbVie announced that its Rinvoq met the primary endpoint in active psoriatic arthritis in its SELECT-PsA 2 Phase III trial.
Novartis is careful to note that Cosentyx showed “numerically higher results versus Humira,” and that there are some statistically significant advantages of the drug over Humira.
ObsEva SA announced that the U.S. Food and Drug Administration has allowed the Company to begin enrolling patients in IMPLANT 3, the U.S pivotal Phase 3 clinical trial of nolasiban in women undergoing embryo transfer following in-vitro fertilization.
The agent is an antibody-based fluorescence-guided approach aimed at improving surgery and clinical outcomes.
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer.
Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving Therapy
Cyclerion Therapeutics had a tough day, announcing the failure of two separate clinical trials for the same drug on the same day.
PRESS RELEASES